Wednesday, April 9
1:00 – 2:00 p.m. ET
Advance registration required

Laura Oswald, Ph.D., assistant member, Department of Health Outcomes and Behavior, Moffitt Cancer Center, will give a talk on “Survivorship in patients with multiple myeloma treated with chimeric antigen receptor T-cell therapy.”

Monday, April 21
1:00 – 2:00 p.m. ET
Advance registration required

Atieh Hajirahimkhan, Ph.D., postdoctoral fellow, Feinberg School of Medicine, Northwestern University, will give a talk on “Reprogramming lipogenic metabolism and inflammation in high-risk breast with licochalcone A: a novel path to cancer prevention.”

Learn more about the seminar series and upcoming talks.

Friday, April 18
3:00 – 4:00 p.m. ET
Advance registration required

Join us to kick off the 2025 season of Building Bridges in Cancer Symptom Science, where we will focus on the complex issue of cancer cachexia. Erin Talbert, Ph.D., from the University of Iowa, and Eric Roeland, M.D., from Oregon Health & Science University, will share their perspectives on developing preclinical models to better understand cancer cachexia and translating this research into clinical interventions.

Learn more about the webinar series.

The Cancer Treatment Tolerability Consortium released three new videos for researchers and clinicians:

ProAE R Package: Advanced Tools for Patient-Reported Adverse Event Analysis in Clinical Trials

• This video provides an overview of a powerful collection of free statistical tools designed for the standardized analysis and visualization of patient-reported adverse event (AE) data in cancer clinical trials.

Improving Cancer Care for Older Adults: The Role of Geriatric Assessments

• This video highlights groundbreaking research showing how geriatric assessments can improve cancer treatment tolerability for patients over age 70.

Understanding the Toxicity Index: A Superior Measure for Adverse Event Analysis

• This video explains the toxicity index—a powerful tool for analyzing and comparing the severity of side effects in patients undergoing cancer treatment.